Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2026, Vol. 31 ›› Issue (10): 1377-1384.doi: 10.12092/j.issn.1009-2501.2026.10.008
Fandong MENG(
), Jingjing FAN, Xin LIU, Lulu KONG(
)
Received:2025-09-01
Revised:2025-10-27
Online:2026-10-26
Published:2026-11-11
Contact:
Lulu KONG
E-mail:504102802@qq.com;lulu-kong@163.com
CLC Number:
Fandong MENG, Jingjing FAN, Xin LIU, Lulu KONG. Predicting dual response failure to semaglutide in obese type 2 diabetes: development and validation of a visual scoring system[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(10): 1377-1384.
| Item | Training set (n=243) | Validation set (n=104) | χ2/t value | P value |
| Sex[n(%)] | 0.736 | 0.391 | ||
| Male | 107(44.03) | 51(49.04) | ||
| Female | 136(55.97) | 53(50.96) | ||
| Age( | 45.37±7.49 | 44.01±7.16 | 1.570 | 0.117 |
| BMI( | 30.86±2.07 | 30.88±2.45 | 0.078 | 0.938 |
| Smoking history[n(%)] | 79(32.51) | 33(31.73) | 0.020 | 0.887 |
| Hypertension[n(%)] | 71(29.22) | 34(32.69) | 0.417 | 0.519 |
| Family history[n(%)] | 64(26.34) | 23(22.12) | 0.691 | 0.406 |
| Disease duration( | 8.08±3.16 | 8.44±3.40 | 0.950 | 0.343 |
| FBG( | 10.62±2.05 | 10.73±2.73 | 0.413 | 0.680 |
| HbA1c( | 9.24±1.70 | 9.02±1.72 | 1.101 | 0.272 |
| TG( | 2.63 ±0.44 | 2.66 ±0.48 | 0.566 | 0.572 |
| TC( | 5.70 ±1.23 | 5.65 ±1.18 | 0.351 | 0.726 |
| LDL-C( | 3.98 ±1.16 | 4.05 ±0.80 | 0.561 | 0.575 |
| HDL-C( | 0.85 ±0.18 | 0.88±0.17 | 1.446 | 0.149 |
| Body fat percentage( | 36.27±2.39 | 35.76±2.89 | 1.707 | 0.089 |
| Visceral fat content( | 890.88±70.04 | 906.55±61.25 | 1.611 | 0.108 |
| CysC( | 0.69±0.08 | 0.71±0.12 | 1.821 | 0.070 |
| Scr( | 71.15±8.22 | 71.00±9.72 | 0.147 | 0.883 |
| SUA( | 343.29±54.37 | 352.26±53.37 | 1.416 | 0.158 |
Table 1 Comparison of clinical characteristics between the training set and validation set
| Item | Training set (n=243) | Validation set (n=104) | χ2/t value | P value |
| Sex[n(%)] | 0.736 | 0.391 | ||
| Male | 107(44.03) | 51(49.04) | ||
| Female | 136(55.97) | 53(50.96) | ||
| Age( | 45.37±7.49 | 44.01±7.16 | 1.570 | 0.117 |
| BMI( | 30.86±2.07 | 30.88±2.45 | 0.078 | 0.938 |
| Smoking history[n(%)] | 79(32.51) | 33(31.73) | 0.020 | 0.887 |
| Hypertension[n(%)] | 71(29.22) | 34(32.69) | 0.417 | 0.519 |
| Family history[n(%)] | 64(26.34) | 23(22.12) | 0.691 | 0.406 |
| Disease duration( | 8.08±3.16 | 8.44±3.40 | 0.950 | 0.343 |
| FBG( | 10.62±2.05 | 10.73±2.73 | 0.413 | 0.680 |
| HbA1c( | 9.24±1.70 | 9.02±1.72 | 1.101 | 0.272 |
| TG( | 2.63 ±0.44 | 2.66 ±0.48 | 0.566 | 0.572 |
| TC( | 5.70 ±1.23 | 5.65 ±1.18 | 0.351 | 0.726 |
| LDL-C( | 3.98 ±1.16 | 4.05 ±0.80 | 0.561 | 0.575 |
| HDL-C( | 0.85 ±0.18 | 0.88±0.17 | 1.446 | 0.149 |
| Body fat percentage( | 36.27±2.39 | 35.76±2.89 | 1.707 | 0.089 |
| Visceral fat content( | 890.88±70.04 | 906.55±61.25 | 1.611 | 0.108 |
| CysC( | 0.69±0.08 | 0.71±0.12 | 1.821 | 0.070 |
| Scr( | 71.15±8.22 | 71.00±9.72 | 0.147 | 0.883 |
| SUA( | 343.29±54.37 | 352.26±53.37 | 1.416 | 0.158 |
| Item | Dual Response Group(n=159) | Non-dual Response Group(n=84) | χ2/t value | P value |
| Sex[n(%)] | 0.292 | 0.589 | ||
| Male | 72(45.28) | 35(41.67) | ||
| Female | 87(54.72) | 49(58.33) | ||
| Age( | 44.96±7.52 | 46.14±7.40 | 1.170 | 0.243 |
| BMI( | 31.50±2.16 | 29.66±1.17 | 7.260 | <0.001 |
| Smoking history[n(%)] | 52(32.70) | 27(32.14) | 0.008 | 0.929 |
| Hypertension[n(%)] | 48(30.19) | 23(27.38) | 0.210 | 0.647 |
| Family history[n(%)] | 43(27.04) | 21(25.00) | 0.118 | 0.731 |
| Disease duration( | 7.04±2.65 | 10.04±3.13 | 7.874 | <0.001 |
| FBG( | 11.54±1.65 | 8.87±1.52 | 12.322 | <0.001 |
| HbA1c( | 9.84±1.67 | 8.10±1.04 | 9.539 | <0.001 |
| TG( | 2.66 ±0.46 | 2.57 ±0.41 | 1.505 | 0.134 |
| TC( | 5.66 ±1.23 | 5.78 ±1.23 | 0.723 | 0.470 |
| LDL-C( | 4.00 ±1.24 | 3.96 ±0.99 | 0.256 | 0.798 |
| HDL-C( | 0.84 ±0.20 | 0.87±0.10 | 1.291 | 0.198 |
| Body fat percentage( | 36.32±2.48 | 36.17±2.22 | 0.465 | 0.643 |
| Visceral fat content( | 909.21±66.29 | 856.19±63.86 | 6.005 | <0.001 |
| CysC( | 0.69±0.08 | 0.70±0.08 | 0.927 | 0.355 |
| Scr( | 70.87±8.36 | 71.70±7.96 | 0.748 | 0.455 |
| SUA( | 343.71±57.43 | 342.49±48.38 | 0.166 | 0.868 |
Table 2 Univariate analysis of non-dual response to semaglutide in obese T2DM patients
| Item | Dual Response Group(n=159) | Non-dual Response Group(n=84) | χ2/t value | P value |
| Sex[n(%)] | 0.292 | 0.589 | ||
| Male | 72(45.28) | 35(41.67) | ||
| Female | 87(54.72) | 49(58.33) | ||
| Age( | 44.96±7.52 | 46.14±7.40 | 1.170 | 0.243 |
| BMI( | 31.50±2.16 | 29.66±1.17 | 7.260 | <0.001 |
| Smoking history[n(%)] | 52(32.70) | 27(32.14) | 0.008 | 0.929 |
| Hypertension[n(%)] | 48(30.19) | 23(27.38) | 0.210 | 0.647 |
| Family history[n(%)] | 43(27.04) | 21(25.00) | 0.118 | 0.731 |
| Disease duration( | 7.04±2.65 | 10.04±3.13 | 7.874 | <0.001 |
| FBG( | 11.54±1.65 | 8.87±1.52 | 12.322 | <0.001 |
| HbA1c( | 9.84±1.67 | 8.10±1.04 | 9.539 | <0.001 |
| TG( | 2.66 ±0.46 | 2.57 ±0.41 | 1.505 | 0.134 |
| TC( | 5.66 ±1.23 | 5.78 ±1.23 | 0.723 | 0.470 |
| LDL-C( | 4.00 ±1.24 | 3.96 ±0.99 | 0.256 | 0.798 |
| HDL-C( | 0.84 ±0.20 | 0.87±0.10 | 1.291 | 0.198 |
| Body fat percentage( | 36.32±2.48 | 36.17±2.22 | 0.465 | 0.643 |
| Visceral fat content( | 909.21±66.29 | 856.19±63.86 | 6.005 | <0.001 |
| CysC( | 0.69±0.08 | 0.70±0.08 | 0.927 | 0.355 |
| Scr( | 70.87±8.36 | 71.70±7.96 | 0.748 | 0.455 |
| SUA( | 343.71±57.43 | 342.49±48.38 | 0.166 | 0.868 |
| Variable | B | SE | Waldχ2 | P value | OR value | 95%CI |
| BMI | ?0.628 | 0.172 | 13.305 | <0.001 | 0.533 | 0.381-0.748 |
| Disease duration | 0.465 | 0.105 | 19.412 | <0.001 | 1.591 | 1.294-1.957 |
| FBG | ?1.053 | 0.194 | 29.388 | <0.001 | 0.349 | 0.238-0.511 |
| HbA1c | ?0.968 | 0.233 | 17.293 | <0.001 | 0.380 | 0.241-0.599 |
| Visceral Fat Content | ?0.011 | 0.004 | 7.078 | 0.008 | 0.989 | 0.981-0.997 |
Table 3 Multivariate logistic regression analysis of factors associated with non-dual response to semaglutide in obese T2DM patients
| Variable | B | SE | Waldχ2 | P value | OR value | 95%CI |
| BMI | ?0.628 | 0.172 | 13.305 | <0.001 | 0.533 | 0.381-0.748 |
| Disease duration | 0.465 | 0.105 | 19.412 | <0.001 | 1.591 | 1.294-1.957 |
| FBG | ?1.053 | 0.194 | 29.388 | <0.001 | 0.349 | 0.238-0.511 |
| HbA1c | ?0.968 | 0.233 | 17.293 | <0.001 | 0.380 | 0.241-0.599 |
| Visceral Fat Content | ?0.011 | 0.004 | 7.078 | 0.008 | 0.989 | 0.981-0.997 |
| 1 | 张思婷, 张继国, 贾小芳, 等. 2018年中国15省份18~65岁居民肥胖与2型糖尿病患病的关联研究[J]. 中华流行病学杂志, 2022, 43 (10): 1596- 1602. |
| 2 |
Liu Y, Luo X. New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation[J]. Front Med, 2022, 16 (1): 17- 24.
doi: 10.1007/s11684-021-0873-2 |
| 3 |
Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial[J]. Lancet, 2021, 397 (10278): 971- 984.
doi: 10.1016/S0140-6736(21)00213-0 |
| 4 |
Kadowaki T, Isendahl J, Khalid U, et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial[J]. Lancet Diab Endocrinol, 2022, 10 (3): 193- 206.
doi: 10.1016/S2213-8587(22)00008-0 |
| 5 |
Pérez-Belmonte LM, Sanz-Cánovas J, García de Lucas MD, et al. Efficacy and safety of semaglutide for the management of obese patients with type 2 diabetes and chronic heart failure in real-world clinical practice[J]. Front Endocrinol (Lausanne), 2022, 13, 851035.
doi: 10.3389/fendo.2022.851035 |
| 6 |
Takahashi Y, Nomoto H, Yokoyama H, et al. Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study)[J]. Diab Obes Metab, 2023, 25 (6): 1503- 1511.
doi: 10.1111/dom.14998 |
| 7 | 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13 (4): 315- 409. |
| 8 |
Thewjitcharoen Y, Yenseung N, Butadej S, et al. Real-world use of once-weekly semaglutide in thai patients with type 2 diabetes mellitus in a private hospital setting[J]. J ASEAN Fed Endocr Soc, 2023, 38 (1): 21- 28.
doi: 10.15605/jafes.038.01.11 |
| 9 |
Rajamand Ekberg N, Bodholdt U, Catarig AM, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Denmark/Sweden multicentre, prospective, observational study[J]. Prim Care Diabetes, 2021, 15 (5): 871- 878.
doi: 10.1016/j.pcd.2021.06.008 |
| 10 |
Garg SK, Kaur G, Haider Z, et al. Efficacy of semaglutide in overweight and obese patients with type 1 diabetes[J]. Diab Technol Ther, 2024, 26 (3): 184- 189.
doi: 10.1089/dia.2023.0490 |
| 11 |
叶惠成, 刘玉华, 尹沛锋, 等. 司美格鲁肽与利拉鲁肽治疗肥胖型2型糖尿病患者疗效比较研究[J]. 临床军医杂志, 2023, 51 (8): 840- 842.
doi: 10.16680/j.1671-3826.2023.08.18 |
| 12 |
靳丽丽, 郄涛, 李立琴. 司美格鲁肽通过调控AMPK/mTOR/ULK1通路介导的自噬减轻缺氧/复氧AC16人心肌细胞炎症损伤[J]. 中国临床药理学与治疗学, 2025, 30 (8): 1058- 1066.
doi: 10.12092/j.issn.1009-2501.2025.08.006 |
| 13 |
Kimura T, Katakura Y, Shimoda M, et al. Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes: Randomized, parallel-group, multicentre, open-label trial (COMING study)[J]. Diabetes Obes Metab, 2023, 25 (12): 3632- 3647.
doi: 10.1111/dom.15258 |
| 14 |
Frazer M, Swift C, Gronroos NN, et al. Real-world hemoglobin A1c changes, prescribing provider types, and medication dose among patients with type 2 diabetes mellitus initiating treatment with oral semaglutide[J]. Adv Ther, 2023, 40 (11): 5102- 5114.
doi: 10.1007/s12325-023-02677-w |
| 15 |
Yabe D, Yamada Y, Kaku K, et al. Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index[J]. J Diabetes Investig, 2022, 13 (7): 1161- 1174.
doi: 10.1111/jdi.13773 |
| 16 |
Hansen KB, Svendstrup M, Lund A, et al. Once-weekly subcutaneous semaglutide treatment for persons with type 2 diabetes: real-world data from a diabetes out-patient clinic[J]. Diabet Med, 2021, 38 (10): e14655.
doi: 10.1111/dme.14655 |
| 17 |
Melzer Cohen C, Mosenzon O, Aharonovich A, et al. Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes[J]. Diab Res Clin Pract, 2025, 222, 112086.
doi: 10.1016/j.diabres.2025.112086 |
| 18 |
Cárdenas-Salas JJ, Sierra Poyatos RM, Luca BL, et al. REAL life study of subcutaneous SEMaglutide in patients with type 2 diabetes in SPain: ambispective, multicenter clinical study. Results in the GLP1-experienced cohort[J]. J Diab Compl, 2024, 38 (12): 108874.
doi: 10.1016/j.jdiacomp.2024.108874 |
| 19 |
Karagiannis T, Malandris K, Avgerinos I, et al. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials[J]. Diabetologia, 2024, 67 (7): 1206- 1222.
doi: 10.1007/s00125-024-06144-1 |
| 20 |
Wolffenbuttel BHR, Brugts MP, Catarig AM, et al. Once-weekly semaglutide use in type 2 diabetes: real-world data from the SURE netherlands observational study[J]. Adv Ther, 2023, 40 (3): 920- 933.
doi: 10.1007/s12325-022-02385-x |
| 21 |
Menzen M, Berentzen TL, Catarig AM, et al. Real-world use of once-weekly semaglutide in type 2 diabetes: results from semaglutide real-world evidence (SURE) Germany[J]. Exp Clin Endocrinol Diabetes, 2023, 131 (4): 205- 215.
doi: 10.1055/a-2007-2061 |
| 22 |
Sherrill CH, Hwang AY. The pursuit of optimal semaglutide dosing in type 2 diabetes continues[J]. Lancet, 2023, 402 (10403): 668- 669.
doi: 10.1016/S0140-6736(23)01233-3 |
| [1] | Rufeng ZHOU, Ying ZHANG, Ziyuan MENG, Jie LIU, Mengqiong SHI, Yong LIAO, Jie XU, Haoran LI, Yanqing TAN, Huilin QIN, Liangliang JIA, Yan YOU. Tormentic acid protects alcohol induced GES-1 cells via regulating Keap-1/Nrf2 and NLRP3 inflammasome signaling pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(8): 1034-1052. |
| [2] | Ailin LU, Yongqing WU, Mengrui YUAN, Hongyi LIU. Mechanism of action of adrenomedullin and its receptors in diabetic peripheral neuropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(8): 1144-1152. |
| [3] | Yi ZHANG, Jie FANG, Shu ZHAO, Jingli YUAN, Xuejun REN. Effect of gender on the efficacy of fospropofol disodium in inhibiting the reaction of gastroscopy insertion [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(7): 908-912. |
| [4] | Jin XU, Jiansheng LI, Zhenhua LIU, Xinli ZHANG, Feng JIN. Advances in molecular mechanisms of immune responses in primary membranous nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(7): 948-956. |
| [5] | Ailin LU, Mengrui YUAN, Yongqing WU, Hongyi LIU. Progress of Chinese medicine intervention in HMGB1 pathway to improve type 2 diabetes mellitus and its complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 827-835. |
| [6] | Mei CHENG, Zhaohui FANG, Jindong ZHAO, Fengxia SHENG, Mengnan MA. Liraglutide combined with metformin on glycolipid metabolism level and intima-media thickness in overweight/obese patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 623-630. |
| [7] | Kang ZENG, Weixin XING, Qingchun MU. Research progress of patchouli alcohol in the treatment of ischemia-related diseases [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 691-699. |
| [8] | Yongjiu JI, Suli ZHOU, Siqi YANG, Yingzhou TU, Chenqi JIANG, Bingyuan ZHANG, Changmao ZHU, Qi ZHANG, Chun YANG, Suwan HU. Median effective dose of oliceridine as an adjunct to propofol sedation in patients with preclinical obesity undergoing same-visit bidirectional endoscopy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 493-499. |
| [9] | Ying ZHOU, Juntong LIU, Qingfeng WANG, Yufeng YANG, Yan SHI. Research progress on pharmacological mechanism of traditional Chinese medicine targeting type 2 diabetes related pathways [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 500-508. |
| [10] | LIU Xing, CHEN Ying. Drug therapy and new technology progress of type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(9): 1215-1223. |
| [11] | JIN Lili, QIE Tao, LI Liqin. Semaglutide alleviates hypoxia/reoxygenation-induced inflammatory injury of AC16 human cardiomyocytes by regulating autophagy through AMPK/mTOR/ULK1 pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(8): 1058-1066. |
| [12] | ZHANG Mengli, WU Fangfang, TAN Zhien, OU Min, LIU Lingjie, LU Na, QIAO Liya, YANG Xiaonan. Effects of branched-chain and aromatic amino acids on type 2 diabetes mellitus and the progress [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(4): 526-532. |
| [13] | LIU Zihan, DU Wenyu, GUO Caihui, WANG Zhi, LI Ying, DONG Zhanjun. Research progress of empagliflozin in the treatment of type 2 diabetes mellitus and cardiovascular and renal benefits [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(3): 412-418. |
| [14] | TAN Yanchen, WANG Wenwen, XIA Jielai, LI Chen. Research on the application of machine learning algorithms in anticancer drug response prediction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 200-208. |
| [15] | YANG Juanjuan, LI Haolin, YANG Tianning, CHENG Weigang, WANG Zhendong, JIN Fangmei, NIAN Fanghong, SU Xiaojun, WANG Jiaqiang, WANG Haiping, WANG Haidong. Inhibition of Inflammation and Bone Destruction in mice with Collagen-induced Arthritis by Zushima Plaster [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(9): 979-987. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||